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Conclusion: A complication rate of 18% was found after less 
invasive surgery for the treatment of spinal metastases. 
Promising clinical outcomes were demonstrated in terms of 
minimal blood loss, high rates of early post-operative 
ambulation and few wound complications, which may allow 
earlier administration of adjuvant oncological treatments. 
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Purpose or Objective: Functional evaluation is crucial in the 
approach of patients, and the most commonly used 
functional evaluation tool in cancer patients has been the 
Karnofsky Scale (KS). A KPS of less than 50% suggests a high 
mortality risk within 6 months. The Tokuhashi scoring system 
(TS) is a survival prediction in patients with spinal metastasis. 
For patients with total TS of 8 or less points, TS predicts a 
survival of 6 months or less. This study aims to compare KPS 
and TS for life expectancy in palliative patients with spinal 
cord compression. 
 
Material and Methods: A sample of 79 patients with cord 
compression diagnosed from 2007 to 2014 was obtained by 
consecutive sampling, and KPS and TS were calculated for 
each patient. The analysis was performed retrospectively, 
with survival data registered until October 2014. Percentage 
of patients with KPS ≤ 50% and TS ≤ 8 are shown and 
compared with the survival percentage.  
 
Results: With an average follow up of 4 months (range 0-45), 
52.5% of the sample showed KPS ≤ 50% and 80.8% TS ≤ 8. At 
dead line, 10.3 % continued walking, 2.6 % needed 
wheelchair, 48.7 % died and 38.5 % were lost in follow up. 
For patients with follow up, 90% with TS ≤ 8 livedless than 6 
months and 90% of patients with KPS ≤ 50% lived less than 6 
months. 
 
Conclusion: Both prognostic scoring systems show similar 
survival rates in groups KPS≤50% and TS≤ 8%, adding evidence 
to the Tokuhashi scale as a predictor of survival. 
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Purpose or Objective: To investigate the feasibility, the 
tolerability and the impact of comorbidity assessment on the 
compliance of adjuvant Intensity Modulated Radiation 
Therapy (IMRT) and simultaneous integrated boost (SIB) in 
elderly patients with a diagnosis of breast cancer after 
breast-conserving surgery (BCS). 
 
Material and Methods: Between 09/2011 to 02/2014, 40 
consecutive women with a diagnosis of early stage breast 
cancer were treated with SIB-IMRT after BCS in our 
Institution. Inclusion criteria were: age ≥ 70 years, pT1 -2 
disease, pN0-1, no neoadjuvant chemotherapy, non-
metastatic disease. A dose prescription of 50 Gy in 25 
fractions was prescribed to the whole breast (PTVbreast) and 
an additional dose of radiation on the tumour bed was 
prescribed (PTVboost). A dose prescription of 60 Gy in 25 
fractions to PTVboost was used in patients with negative 
margins after surgery, whereas if the margins were close (< 1 
mm) or positive (without a new surgical resection) a dose of 
64 Gy was prescribed. Charlson Comorbidity Index (CCI) was 
used for comorbidity scoring. All patients were followed with 
periodic clinical evaluation. Acute and late toxicity were 
scored using the EORTC/RTOG radiation morbidity score 
system. Both patient and physician recorded cosmetic 
outcome evaluation with a subjective judgment scale at the 
time of scheduled follow-up. 
 
Results: Median follow-up was 36 months. At the time of the 
analysis, OS and LC rates were 100%. All patients completed 
the SIB-IMRT without interruptions. Acute skin toxicity was 
recorded as follow: grade 0 in 5 patients (12.5%), grade 1 in 
25 cases (62.5%), grade 2 in 10 patients (25%). Regarding late 
adverse events, skin toxicity was registered as follow: grade 
0 in 27 patients (67.5%), grade 1 in 13 cases (32.5%). No 
toxicity ≥ grade 2 was registered. At statistical analysis, the 
presence of comorbidities and the breast volume > 700cc 
were related to skin grade 2 acute toxicity (p=0.01, p=0.04). 
In terms of cosmetic results, 98% and 2%of patients 
considered the result as good /excellent and as fair after RT, 
respectively. No patients had a poor cosmetic outcome. 
 
Conclusion: These data support the feasibility and safety of 
SIB-IMRT in elderly patients with a diagnosis of breast cancer 
following BCS with acceptable acute and late treatment-
related toxicity. Moreover, the absence of comorbidity 
reduced the risk of acute radiation side effects. 
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Purpose or Objective: To report about clinical outcome of 
stereotactic body radiation therapy (SBRT) in the treatment 
of oligometastatic disease in elderly patients affected by 
colorectal cancer. 
 
Material and Methods: Patients with 1–4 inoperable 
metastases were treated with SBRT. Dose prescription ranged 
from 40 to 75Gy in 3–8 fractions. SBRT was delivered using 
the volumetric modulated arc therapy technique with 
flattening filter-free photon beams. The primary end points 
were in-field local control (LC) and toxicity. Secondary end 
points was overall survival (OS). 
 
Results: 52 patients with 57 total metastases were treated. 
Mean age was 79.85 years (range 73.57-88.56). 47 patients 
(90.4%) had a single lesion; the remaining had 2 lesions. 34 
lesions (59.6%) were located in the liver, 18 (31.6%) in the 
lungs and the remaining 5 (8.8%) were nodal or adrenal 
metastases. Local response was observed for 35 lesions 
(61.4%), with 19 complete responses and 16 partial 
responses, while local progression in 18 lesions (31.6%); 
stable disease was recorded in 4 cases (7%). Actuarial 1, 2 
and 3 year LC was 92%, 78 % and 71%. At time of analysis, 
with a mean follow up of 2.2 years (range 0.2-4.9), 38 
patients (73,1%) were still alive, while 14 (26.9%) died (11 
patients died for disease progression). Actuarial 1, 2 and 3 
year OS were 98%, 89% and 61,1% respectively. Treatment-
related Grade 2 toxicity was observed in two patients (3.8%); 
Grade 1 toxicity in five patients (9.6%) and no toxicity was 
observed in 86.6% of the cases. No G3-4 toxicity was 
recorded. 
 
Conclusion: SBRT is a safe and effective therapeutic option 
for the treatment of oligometastatic disease in the elderly 
affected by colorectal cancer with acceptable rates of LC and 
low treatment related toxicity. The use of SBRT for 
oligometastatic disease in the elderly can be considered as a 
valuable approach, particularly for patients with fragile 
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Purpose or Objective: Purpose: To analyze feasibility and 
toxicity of radical hypofractionated RT schedules in elderly 
patients with NSCLC 
 
Material and Methods: Material and methods: Elderly 
patients (≥70 years old) affected by stage III inoperable 
NSCLC were treated in our institution with radical IMRT 
(VMAT RA) according to moderately hypofractionated 
schedules: 56 Gy/20 fractions or 55 Gy/22 fractions or 50 
Gy/20 fractions depending on dose constraints of adjacent 
organs at risk. Patients underwent simulation CT in supine 
position, immobilized with a thermoplastic mask. PET CT was 
performed for simulation and coregistered with CT. Primary 
end point of this analysis were acute and late toxixcities, 
secondary end points were local control and overall survival. 
 
Results: Results: 41 patients, treated between January 2013 
and April 2015, were included in this analysis. Mean age was 
78.59 years (range 70-86). 22 patients were staged IIIA, 19 
patients IIIB. All but one patients had pathological nodal 
involvement (N1:5, N2: 24, N3: 11). Most of patients were 
unsuitable for chemotherapy for comorbidities and poor 
general conditions. 15 patients received chemotherapy 
before RT, concomitant RT-CHT was not allowed. Acute G1-2 
toxicity was recorded in 25 patients(61), mostly esophagitis, 
dyspnea and dry cough. Late toxicity was recorded in 13 
patients, the most reported side effects were pneumonitis 
and dyspnea. No G3 or G4 acute or late toxicity were 
recorded. A complete response was obtained in two patients, 
26 showed a partial response, while progressive disease was 
recorded in 2 cases. At time of analysis, with a mean follow 
up of 9.89 months (range 1.08-25.43), 17 patients died for 
disease progression, one patient died for other causes, 8 
patients were alive with distant metastases and 15 were alive 
without distant progression. Actuarial OS at 1 and 2 years 
were 51.3% and 35.1% respectively. Mean estimated OS was 
15.12 months (range 12.02-18.22). Actuarial local control at 1 
and 2 years were 72%. 10 patients experienced local 
progression. Mean estimated LC was 12.4 months (range 9.6-
15.1). 
 
Conclusion: Conclusion: Radical hypofractionated IMRT 
(VMAT RA) is a valid treatment for locally advanced 
inoperable NSCLC in elderly frail patients . Our study shows 
that this approach is safe and feasible also in a fragile elder 
population. Survival data are satisfactory. 
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Purpose or Objective: To assess the efficacy and safety of a 
SHort-course Accelerated RadiatiON therapy (SHARON) 
regimen in the palliative treatment of locally advanced or 
metastatic cancers in elderly patients.  
 
Material and Methods: Eligibility criteria of this analysis 
(pooled analysis of 3 phase II studies) were: patients with 
histologically confirmed solid cancers, age ≥ 80 years, 
patients with an expected survival > 3 months and Eastern 
Cooperative Oncology Group (ECOG) performance status of ≤ 
3. The primary endpoint was to evaluate the symptoms 
response rate produced by a radiotherapy regimen based on 
the delivery of 4 radiotherapy fractions (5 Gy per fraction) 
with a twice daily fractionation in two consecutive days 
 
Results: Twenty-four patients were included in this analysis. 
Characteristics of the patients were: male/female: 17/7; 
median age: 87.0 years (range: 80-98). ECOG performance 
status was < 3 in 16 patients (66.7%). Six patients (25.0%) had 
locally advanced thoracic cancers, 13 patients (54.2%) had 
advanced primary or metastatic H&N tumors and 5 patients 
(20.8%) had complicated bone metastases. With a median 
follow-up time of 5.0 months (range, 1 to 8 months), eleven 
G1-G2 acute skin (45.9%) and G1-2 mucositis (12.5%) 
toxicities were recorded. One patient (4.2%) experienced G1 
acute gastro-intestinal toxicity and only 1 patient (4.2%) 
experienced G3 acute mucositis. Of 24 symptomatic patients, 
19 showed an improvement or resolution of baseline 
symptoms (overall palliative response rate: 79.2%). Three-
months overall survival was 89.7% (median survival time: 7.0 
months; 95%CI 5.4-8.6 mo). Median survival without 
symptoms progression was 5.0 months (95%CI: 2.5-7.5 mo). In 
23 patients with pain, a significant reduction of this symptom 
was recorded in terms of VAS (mean baseline VAS vs mean 
VAS after treatment: 3.9 versus 1.7, p=0.001).  
 
Conclusion: Short-course accelerated radiotherapy in locally 
advanced or metastatic cancers is effective in terms of 
symptom relief and well tolerated even in older patients. 
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Purpose or Objective: The optimal treatment of bladder 
cancer has been a subject of continuous controversy. In North 
America, as well as in Europe, the radical cistectomy as the 
standard option for invasive bladder cancer. In the western 
countries the elderly ones constitute the part of the 
population in more rapid growth and, insofar, the group to 
